Data presented at ECCO congress supports switching from Remicade® to biosimilar infliximab

Ten independent studies validate the growing bank of real-life clinical evidence to support switching patients from the reference infliximab (Remicade®) to biosimilar infliximab

Source: Pharmacy Europe - March 22, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Biosimilars Healthcare professionals Practical therapeutics Patient care Research European Crohn ’s and Colitis Organisation ibd immunogenicity infliximab Latest News remicade switching ulcerative colitis Source Type: news